Liz Homans, CEO of Lyell Immunopharma, discusses how the company is tackling one of the hottest topics in cancer treatment: how to deploy cell therapy techniques to improve outcomes for patients with solid tumor cancers. She talks about how the technologies Lyell has developed are enabling it to advance multiple types of cell therapies, the importance of manufacturing for advancing cell therapy, and the role advanced data and analytics capabilities and digital manufacturing processes may play in improving access to care.
Liz Homans has served as our Chief Executive Officer and member of our board of directors since August 2020. From September 2018 to August 2020, she served as our President and the operational lead as we grew in size, scope and ambition. From July 2009 to May 2018, Ms. Homans served in multiple senior leadership positions at Genentech, including Vice President, U.S. Sales and Marketing Leader for Breast Cancer, Vice President, U.S. Sales and Marketing Leader for Xolair, Vice President, Global Regulatory Operations Leader and Vice President, Global Product Strategy, HER2 Franchise. From May 2004 through November 2007, Ms. Homans served as Executive Director, Project Leadership and Portfolio Management at Jazz Pharmaceuticals, Inc. Ms. Homans received an MBA from Columbia University in the City of New York and a B.A. in German and Economics from Bates University.